Please refer attached annual report for FY2024-25
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Emmessar Biotech & Nutrition Ltd has submitted its 33rd Annual Report for FY2024-25 to BSE under SEBI LODR Regulation 34(1), along with the notice for its Annual General Meeting scheduled for September 26, 2025 via video conferencing. The AGM will consider three resolutions: adopting the audited financial statements for FY ended March 31, 2025, reappointing Dr. Anuradha Srinivasa Raghavan as director (retiring by rotation), and approving revised remuneration of Rs. 2-3 lakh per month for Managing Director Mr. Srinivasa Raghavan Mathurakavi Ayyangar from FY2025-26 onwards. The company operates in the pharmaceutical space with VedaCeuticals brand products (Muscleflex, CalmCream, MagiCream, RESQ) blending Ayurveda with modern pharma. Two non-executive directors stepped down during the year (Mrs. Rajalakshmi Srinivasa Raghavan and Mr. Anantharama S Subramanian). The Managing Director remuneration approval is being sought as a Special Resolution under Schedule V of the Companies Act, referencing 'Reasons for Loss or Inadequate profits'.
This is a routine annual report and AGM notice filing. Shareholders should note the September 26, 2025 AGM date and e-voting window (September 23-25, 2025). The reference to 'inadequate profits' in the explanatory statement and the need for a special resolution to pay MD remuneration hints at weak profitability, which is the key area for investor attention in the actual financial statements.